title: The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.
abstract: OBJECTIVE
  Patients with stage I ovarian cancer show a high incidence of recurrent disease ranging from 30% to 50%, which may be associated with a shortened survival. Therefore, a subset of early-stage patients with poor prognostic factors who are most likely to present with recurrent disease in the next few years may benefit from adjuvant treatment.
  
  
  METHODS
  In this pilot study, we evaluated the efficacy of combination chemotherapy including intraperitoneal mitoxantrone (12 mg/ml) and cisplatinum (75 mg/ml) on day 1, in addition to intravenous ifosfamide (4000 mg/m2) given on day 15 with mesna protection. Thirteen patients with a median age of 44 years were included in the study.
  
  
  RESULTS
  Following a median of 5 cycles of chemotherapy, 12 patients had a complete response (92.3%), while one patient had progressive disease. At the latest follow-up, ten patients were alive with no evidence of disease, two patients had died and one patient was lost to follow-up. Overall and progression-free survival rates at eight years were 82.5+/-11.3% and 83.9+/-10.5%, respectively. Excluding grade 3 and 4 abdominal pain in three (23.1%) patients, there were no serious complications associated with this combination. Dose delay not longer than one week was observed in 3 cycles (5.6%). Port-related complications observed in three patients were colonic perforation, hematoma and leakage.
  
  
  CONCLUSIONS
  This combination has moderate efficacy and tolerable toxicity. However, further studies are required to make definite conclusions regarding the efficacy of this combination in the adjuvant setting in patients with high-risk early stage ovarian carcinoma.
authors.affiliation: Medical Oncology, Institute of Oncology, University of Istanbul, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Topuz
authors.forename: Y
authors.initials: Y
authors.lastname: Eralp
authors.forename: P
authors.initials: P
authors.lastname: Saip
authors.forename: A
authors.initials: A
authors.lastname: Aydiner
authors.forename: F
authors.initials: F
authors.lastname: Taş
authors.forename: Y
authors.initials: Y
authors.lastname: Saliho
authors.forename: Y
authors.initials: Y
authors.lastname: Salihoğlu
authors.forename: S
authors.initials: S
authors.lastname: Berkman
authors.forename: E
authors.initials: E
authors.lastname: Bengisu
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018269:Carcinoma, Endometrioid / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000473:pathology; D004361:Drug Tolerance; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D008942:Mitoxantrone; D002945:Cisplatin; D007069:Ifosfamide